-
1دورية أكاديميةOxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.
المؤلفون: Strickson S; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; These authors contributed equally to this work., Houslay KF; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; These authors contributed equally to this work., Negri VA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ohne Y; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Ottosson T; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Dodd RB; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Huntington CC; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Baker T; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Li J; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Stephenson KE; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., O'Connor AJ; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sagawe JS; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Killick H; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Moore T; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rees DG; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Koch S; Imaging & Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Sanden C; Experimental Medical Sciences, Lund University, Lund, Sweden.; Medetect AB, Lund, Sweden., Wang Y; Imaging & Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Gubbins E; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ghaedi M; Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Kolbeck R; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Current: Spirovant Sciences, Philadelphia, PA, USA., Saumyaa S; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Erjefält JS; Experimental Medical Sciences, Lund University, Lund, Sweden.; Allergology and Respiratory Medicine, Lund University, Skåne University Hospital, Lund, Sweden., Sims GP; Bioscience Immunology, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Humbles AA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Current: Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Romero Ros X; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; These authors contributed equally to this work., Cohen ES; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK suzanne.cohen@astrazeneca.com.; These authors contributed equally to this work.
المصدر: The European respiratory journal [Eur Respir J] 2023 Sep 28; Vol. 62 (3). Date of Electronic Publication: 2023 Sep 28 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
مواضيع طبية MeSH: Interleukin-33*/genetics , Interleukin-33*/metabolism , Pulmonary Disease, Chronic Obstructive*/genetics , Pulmonary Disease, Chronic Obstructive*/metabolism , Pulmonary Disease, Chronic Obstructive*/pathology, Humans ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; ErbB Receptors ; Interleukin-1 Receptor-Like 1 Protein ; Oxidation-Reduction ; Receptor for Advanced Glycation End Products/metabolism
-
2دورية أكاديمية
المؤلفون: Spooner W; Eagle Genomics Ltd., Biodata Innovation Centre, Wellcome Genome Campus, Hinxton, Cambridge, CB10 3DR, UK.; Genomics England, QMUL Dawson Hall, London, EC1M 6BQ, UK., McLaren W; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK., Slidel T; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Finch DK; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Butler R; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Campbell J; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Eghobamien L; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Rider D; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Kiefer CM; MedImmune, Gaithersburg, MD, 20878, USA., Robinson MJ; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Hardman C; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Cunningham F; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK., Vaughan T; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK., Flicek P; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK., Huntington CC; MedImmune Ltd., Granta Park, Cambridge, CB21 4QR, UK. HuntingtonC@medimmune.com.
المصدر: Nature communications [Nat Commun] 2018 Oct 08; Vol. 9 (1), pp. 4128. Date of Electronic Publication: 2018 Oct 08.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
مواضيع طبية MeSH: Drug Design* , Haplotypes*, Computational Biology/*methods , Precision Medicine/*methods , Proteins/*genetics, Computer-Aided Design ; Genome, Human/genetics ; Genomics/methods ; Humans ; Proteome/genetics ; Reproducibility of Results ; Software